Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD
SGLT-2 inhibitors have not been evaluated in patients with stage 5 CKD (CKD 5; eGFR, ≤15 mL/minute/1.73 m2). Investigators in Taiwan retrospectively assessed 5 years of outcome data for nearly 48,000 ...
28 Touko 20245min
Episode 294: 293. Should GLP-1 Agonist be Held Prior to Procedure or Surgery?
glucagon-like peptide-1 (GLP-1) receptor agonists can delay gastric emptying, the American Society of Anesthesiologists (ASA) say For patients on daily dosing consider holding GLP-1 agonists on the da...
24 Touko 20245min
Episode 293: 292. An Antibiotic RCT for Community Acquired Pneumonia
But now we have RCT data—278 adults with moderate CAP who were hospitalized (but not in intensive care) to receive either a β-lactam antimicrobial plus clarithromycin or a β-lactam alone. (all patient...
23 Touko 20244min
Episode 292: 291. Does CHATGPT Have a Career In Pathology?
AI technology was highly accurate at identifying malignancies and tumor origins — as accurate as senior pathologists, and significantly more accurate than junior pathologists. Patients with cancer o...
22 Touko 20245min
Episode 291: 290. When Should You Use IV Albumin?
HERE IS WHEN IT IS RECOMMENDED TO USE ALBUMIN In patients with cirrhosis and spontaneous bacterial peritonitis, to substantially limit kidney impairment and mortality (low-certainty evidence) THIS IS ...
21 Touko 20246min
Episode 290: 289. Which GLP-1 is the Best Weight Loss Drug?
The results for weight loss was Tirzepatide also known as mounjaro – 8.5 kg Semaglutide also known as Ozempic -3.1 kg lost Liraglutide aka Victoza – 1.3 kg lostTirzepatide also known as mounjaro – 8...
20 Touko 20245min
Episode 289: 288. An RCT for Time Restricted Eating!
41 adults (mean age, 59) with obesity (mean weight, 99 kg) and prediabetes or diet-controlled diabetes – everyone got the same diet. Same micro- and macronutrient composition; same calorie amounts Fo...
17 Touko 20245min
Episode 288: 287. A New FDA Approved Drug for Chronic Rhinosinusitis
recipients were more likely than placebo recipients to report much or very much improvement (55% vs. 25%) which isn’t shocking because half of the people were not getting medicinethey also report that...
16 Touko 20248min
